NuvOx Pharma has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).
Search
Recent Posts
See All"We are honored and excited to have Jon Saxe join our board," said Evan Unger MD, President and CEO of NuvOx. "His broad knowledge of the industry and years of experience both as an executive and in